Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Amyotrophic Lateral Sclerosis Topic Center

News
ALS Assessments Should Include Comprehensive Sensory Testing, Researchers Advise
06/23/2022
Jolynn Tumolo
Neuroimaging of patients with amyotrophic lateral sclerosis (ALS) showed degeneration of anatomical structures involved in somatosensory, visual, and auditory processing.
Neuroimaging of patients with amyotrophic lateral sclerosis (ALS) showed degeneration of anatomical structures involved in somatosensory, visual, and auditory processing.
Neuroimaging of patients with...
06/23/2022
Neurology
The Neurologist Is In podcast.
Podcasts
The Neurologist Is In, Episode 10, Part 1: Providing Interdisciplinary Patient Care With Neuromuscular Specialist Dr Madhu Mona Soni
06/20/2022
In this episode, Dr Rachel Salas, MD, MEd, sits down with Madhu Mona Soni, MD, FAAN, to discuss exciting developments in neuromuscular neurology, the power of interdisciplinary patient care, and more!
In this episode, Dr Rachel Salas, MD, MEd, sits down with Madhu Mona Soni, MD, FAAN, to discuss exciting developments in neuromuscular neurology, the power of interdisciplinary patient care, and more!
In this episode, Dr Rachel...
06/20/2022
Neurology
DNA.
Quiz
Which protein may serve as a biomarker for ALS?
06/16/2022
Take the quiz now to test your knowledge!
Take the quiz now to test your knowledge!
Take the quiz now to test your...
06/16/2022
Neurology
News
As Understanding of ALS Grows, Novel Therapies Anticipated
06/15/2022
Jolynn Tumolo
Since the discovery of SOD1 nearly 30 years ago, the identification of genes linked with amyotrophic lateral sclerosis (ALS) has progressed from a fairly slow start to the current period of quickly emerging insight.
Since the discovery of SOD1 nearly 30 years ago, the identification of genes linked with amyotrophic lateral sclerosis (ALS) has progressed from a fairly slow start to the current period of quickly emerging insight.
Since the discovery of SOD1...
06/15/2022
Neurology
News
Phase 3 Trial Shows Ultrahigh-Dose Methylcobalamin Slows Progression of Early-Stage ALS
06/01/2022
Jolynn Tumolo
A twice-weekly intramuscular injection of ultrahigh-dose methylcobalamin appears to slow clinical progression in patients with early-stage amyotrophic lateral sclerosis (ALS).
A twice-weekly intramuscular injection of ultrahigh-dose methylcobalamin appears to slow clinical progression in patients with early-stage amyotrophic lateral sclerosis (ALS).
A twice-weekly intramuscular...
06/01/2022
Neurology
News
Some Hypertension, Diabetes Medications May Reduce ALS Risk
06/01/2022
Jolynn Tumolo
Regular use of common medications for blood pressure and diabetes management could protect against the development of amyotrophic lateral sclerosis (ALS), according to new study results published in Neurological Sciences.
Regular use of common medications for blood pressure and diabetes management could protect against the development of amyotrophic lateral sclerosis (ALS), according to new study results published in Neurological Sciences.
Regular use of common...
06/01/2022
Neurology
News
Robotic Device Improves Walking in Patients With ALS
04/27/2022
Jolynn Tumolo
A wearable, robotic device designed to support movement preserved, and in some cases improved, gait ability in patients with ALS, according to new research.
A wearable, robotic device designed to support movement preserved, and in some cases improved, gait ability in patients with ALS, according to new research.
A wearable, robotic device...
04/27/2022
Neurology
News
NFL Players Almost 4 Times More Likely to Die From ALS
04/25/2022
Jolynn Tumolo
Amyotrophic lateral sclerosis (ALS) incidence and mortality rates are nearly 4 times higher in National Football League (NFL) players compared with the US male population, according to a study published in JAMA Network Open.
Amyotrophic lateral sclerosis (ALS) incidence and mortality rates are nearly 4 times higher in National Football League (NFL) players compared with the US male population, according to a study published in JAMA Network Open.
Amyotrophic lateral sclerosis...
04/25/2022
Neurology
News
Cutaneous Cytoplasmic TDP-43 Shows Potential as ALS Biomarker
04/25/2022
Jolynn Tumolo
Significantly increased levels of the protein TDP-43 in the epidermis and in the cytoplasm of dermal cells may offer a biomarker for ALS, according to a study published in the journal Cells.
Significantly increased levels of the protein TDP-43 in the epidermis and in the cytoplasm of dermal cells may offer a biomarker for ALS, according to a study published in the journal Cells.
Significantly increased levels...
04/25/2022
Neurology
News
Resting-State EEG Reveals Patterns in Amyotrophic Lateral Sclerosis
02/28/2022
Recent data show that novel phenotyping using neuroelectric signal analysis can help identify four different disease subtypes of amyotrophic lateral sclerosis (ALS), according to findings published in Brain.
Recent data show that novel phenotyping using neuroelectric signal analysis can help identify four different disease subtypes of amyotrophic lateral sclerosis (ALS), according to findings published in Brain.
Recent data show that novel...
02/28/2022
Neurology

Advertisement

Advertisement

News

A middle-aged male running
News
Moderate Physical Activity May Mitigate ALS Risk for Male Patients
07/25/2024
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in...
07/25/2024
Neurology
Doctors examine brain scans
News
Rate of Frontotemporal Dementia in Patients With ALS Higher Than Previous Estimates
03/04/2024
Jolynn Tumolo
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients...
03/04/2024
Neurology
The US Food and Drug Administration headquarters sign.
News
FDA Declines Accelerated Approval for Novel ALS Drug
01/05/2024
Brionna Mendoza
The US Food and Drug Administration (FDA) declined to grant accelerated approval of the experimental drug CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS).
The US Food and Drug Administration (FDA) declined to grant accelerated approval of the experimental drug CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS).
The US Food and Drug...
01/05/2024
Neurology
Brain health
News
Environmental Pollutants Linked With Increased ALS Risk, Mortality
11/21/2023
Jolynn Tumolo
An environmental risk score was associated with amyotrophic lateral sclerosis (ALS) risk and mortality in a Michigan cohort.
An environmental risk score was associated with amyotrophic lateral sclerosis (ALS) risk and mortality in a Michigan cohort.
An environmental risk score was...
11/21/2023
Neurology
Polygenic Score for ALS Reflects an Individual’s Cumulative Genetic Risk
News
Polygenic Score for ALS Reflects an Individual’s Cumulative Genetic Risk
07/18/2023
Jolynn Tumolo
A novel scoring system may help predict a person’s risk of developing amyotrophic lateral sclerosis (ALS) by weighing the combined effects of common genetic variants, according to a study published online in Neurology Genetics. “This...
A novel scoring system may help predict a person’s risk of developing amyotrophic lateral sclerosis (ALS) by weighing the combined effects of common genetic variants, according to a study published online in Neurology Genetics. “This...
A novel scoring system may help...
07/18/2023
Neurology
Cerebrospinal Fluid Biomarker May Inform ALS Diagnosis, Treatment
News
Cerebrospinal Fluid Biomarker May Inform ALS Diagnosis, Treatment
06/14/2023
Jolynn Tumolo
A newly discovered potential biomarker may aid in the diagnosis and treatment of sporadic amyotrophic lateral sclerosis (ALS), according to a research letter published in the Journal of Neurology, Neurosurgery, and Psychiatry. 
A newly discovered potential biomarker may aid in the diagnosis and treatment of sporadic amyotrophic lateral sclerosis (ALS), according to a research letter published in the Journal of Neurology, Neurosurgery, and Psychiatry. 
A newly discovered potential...
06/14/2023
Neurology
A hand chooses a happy face with a neutral and unhappy face next to them
News
ALS Patients Evaluate Facial Expressions Differently, Even Without Cognitive Impairment
05/18/2023
Brionna Mendoza
Patients with amyotrophic lateral sclerosis (ALS) exhibit different gaze patterns when visually scanning human facial expressions compared to healthy controls, according to new study findings.
Patients with amyotrophic lateral sclerosis (ALS) exhibit different gaze patterns when visually scanning human facial expressions compared to healthy controls, according to new study findings.
Patients with amyotrophic...
05/18/2023
Neurology
News
FDA Advisory Committee Backs Accelerated Approval of Tofersen for SOD1-ALS
04/24/2023
Jolynn Tumolo
Members of the committee agreed 9-0 that a demonstrated reduction in plasma neurofilament light chain (NfL) concentration in patients with SOD1-ALS is reasonably likely to predict clinical benefit.
Members of the committee agreed 9-0 that a demonstrated reduction in plasma neurofilament light chain (NfL) concentration in patients with SOD1-ALS is reasonably likely to predict clinical benefit.
Members of the committee agreed...
04/24/2023
Neurology
News
ALS Therapy Receives FDA Orphan Drug Designation
03/21/2023
Jolynn Tumolo
The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation to RAG-17, a novel short interfering RNA (siRNA) modality for the treatment of patients with amyotrophic lateral sclerosis (ALS), biopharmaceutical company...
The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation to RAG-17, a novel short interfering RNA (siRNA) modality for the treatment of patients with amyotrophic lateral sclerosis (ALS), biopharmaceutical company...
The US Food and Drug...
03/21/2023
Neurology
News
Prototype Soft Robotic Wearable Restores Arm Function for ALS Patients, Hints at Future of Assistive Technology
03/16/2023
Brionna Mendoza
A soft robotic wearable prototype that significantly assists upper arm and shoulder movement in people with amyotrophic lateral sclerosis (ALS) has been developed by a team of researchers from Harvard.
A soft robotic wearable prototype that significantly assists upper arm and shoulder movement in people with amyotrophic lateral sclerosis (ALS) has been developed by a team of researchers from Harvard.
A soft robotic wearable...
03/16/2023
Neurology
Fremanezumab Shows Positive Results for Pediatric Use in Phase 3 Trial
News
Fremanezumab Shows Positive Results for Pediatric Use in Phase 3 Trial
08/08/2024
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive...
08/08/2024
Neurology
brain waves
News
High-Dose Statins May Not Benefit Patients With Mild Ischemic Stroke
08/08/2024
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose...
08/08/2024
Neurology
An illustration of a healthcare provider conducting a telehealth appointment
News
Teleneurology Visits Acceptable to Patients Across Neurologic Conditions
08/05/2024
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic...
08/05/2024
Neurology
The US Food and Drug Administration headquarters sign.
News
DMD Gene Therapy Indication Expanded to Include Boys 4 and Older
08/01/2024
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an...
08/01/2024
Neurology
A person walks down a boarded path with sunlight and trees in the background
News
Backward Walking Speed Reserve Reflects Disease Severity in Patients With MS
07/30/2024
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve,...
07/30/2024
Neurology
FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment
News
FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment
07/29/2024
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod...
07/29/2024
Neurology
A middle-aged male running
News
Moderate Physical Activity May Mitigate ALS Risk for Male Patients
07/25/2024
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in...
07/25/2024
Neurology
Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy
News
Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy
07/23/2024
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug...
07/23/2024
Neurology
Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults
News
Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults
07/22/2024
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine. 
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine. 
Chronic loneliness was...
07/22/2024
Neurology
a hand breaks a wooden human figurine in half
News
Atogepant Reduces Migraine Days in Patients With Pain Medication Overuse
07/18/2024
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related...
07/18/2024
Neurology

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement